White matter hyperintensities combined with serum NLRP3 in diagnosis of cognitive impairment in patients with cerebral small vessel disease

References

• Li Q, Yang Y, Reis C, et al. Cerebral small vessel disease. Cell Transplant. 2018;27(12):1711–1722. doi: 10.1177/0963689718795148.
   PubMed Web of Science ®Google Scholar
• Cuadrado-Godia E, Dwivedi P, Sharma S, et al. Cerebral small vessel disease: a review focusing on pathophysiology, biomarkers, and machine learning strategies. J Stroke. 2018;20(3):302–320. doi: 10.5853/jos.2017.02922.
   PubMed Web of Science ®Google Scholar
• Østergaard L, Engedal TS, Moreton F, et al. Cerebral small vessel disease: capillary pathways to stroke and cognitive decline. J Cereb Blood Flow Metab. 2016;36(2):302–325. doi: 10.1177/0271678X15606723.
   PubMed Web of Science ®Google Scholar
• Zanon Zotin MC, Sveikata L, Viswanathan A, et al. Cerebral small vessel disease and vascular cognitive impairment: from diagnosis to management. Curr Opin Neurol. 2021;34(2):246–257. doi: 10.1097/WCO.0000000000000913.
   PubMed Web of Science ®Google Scholar
• Zhang CE, Wong SM, Uiterwijk R, et al. Blood-brain barrier leakage in relation to white matter hyperintensity volume and cognition in small vessel disease and normal aging. Brain Imaging Behav. 2019;13(2):389–395. doi: 10.1007/s11682-018-9855-7.
   PubMed Web of Science ®Google Scholar
• van Leijsen EMC, Tay J, van Uden IWM, et al. Memory decline in elderly with cerebral small vessel disease explained by temporal interactions between white matter hyperintensities and hippocampal atrophy. Hippocampus. 2019;29(6):500–510. doi: 10.1002/hipo.23039.
   PubMed Web of Science ®Google Scholar
• Stewart CR, Stringer MS, Shi Y, et al. Associations between white matter hyperintensity burden, cerebral blood flow and transit time in small vessel disease: an updated meta-analysis. Front Neurol. 2021;12:647848. doi: 10.3389/fneur.2021.647848.
   PubMed Web of Science ®Google Scholar
• Huang Y, Xu W, Zhou R. NLRP3 inflammasome activation and cell death. Cell Mol Immunol. 2021;18(9):2114–2127. doi: 10.1038/s41423-021-00740-6.
   PubMed Web of Science ®Google Scholar
• Van Zeller M, Dias D, Sebastião AM, et al. NLRP3 inflammasome: a starring role in amyloid-β- and Tau-driven pathological events in alzheimer’s disease. J Alzheimers Dis. 2021;83(3):939–961. doi: 10.3233/JAD-210268.
   PubMed Web of Science ®Google Scholar
• He W, Hu Z, Zhong Y, et al. The potential of NLRP3 inflammasome as a therapeutic target in neurological diseases. Mol Neurobiol. 2023;60(5):2520–2538. doi: 10.1007/s12035-023-03229-7.
   PubMed Web of Science ®Google Scholar
• Liu T, Wang X, Guo F, et al. Lysophosphatidylcholine induces apoptosis and inflammatory damage in brain microvascular endothelial cells via GPR4-mediated NLRP3 inflammasome activation. Toxicol in Vitro. 2021;77:105227. doi: 10.1016/j.tiv.2021.105227.
   PubMedGoogle Scholar
• Cicolari S, Catapano AL, Magni P. Inflammaging and neurodegenerative diseases: role of NLRP3 inflammasome activation in brain atherosclerotic vascular disease. Mech Ageing Dev. 2021;195:111467. doi: 10.1016/j.mad.2021.111467.
   PubMed Web of Science ®Google Scholar
• Shams M, Shams S, Martola J, et al. MRI markers of small vessel disease and the APOE allele in cognitive impairment. Front Aging Neurosci. 2022;14:897674. doi: 10.3389/fnagi.2022.897674.
   PubMedGoogle Scholar
• Liu Y, Dong YH, Lyu PY, et al. Hypertension-induced cerebral small vessel disease leading to cognitive impairment. Chin Med J. 2018;131(5):615–619. doi: 10.4103/0366-6999.226069.
   PubMed Web of Science ®Google Scholar
• Liu X, Sun P, Yang J, et al. Biomarkers involved in the pathogenesis of cerebral small-vessel disease. Front Neurol. 2022;13:969185. doi: 10.3389/fneur.2022.969185.
   PubMed Web of Science ®Google Scholar
• Alber J, Alladi S, Bae HJ, et al. White matter hyperintensities in vascular contributions to cognitive impairment and dementia (VCID): knowledge gaps and opportunities. Alzheimers Dement. 2019;5(1):107–117. doi: 10.1016/j.trci.2019.02.001.
   Web of Science ®Google Scholar
• Hu HY, Ou YN, Shen XN, et al. White matter hyperintensities and risks of cognitive impairment and dementia: a systematic review and meta-analysis of 36 prospective studies. Neurosci Biobehav Rev. 2021;120:16–27. doi: 10.1016/j.neubiorev.2020.11.007.
   PubMed Web of Science ®Google Scholar
• d’Arbeloff T, Elliott ML, Knodt AR, et al. White matter hyperintensities are common in midlife and already associated with cognitive decline. Brain Commun. 2019;1:fcz041.
   PubMedGoogle Scholar
• Giese AK, Schirmer MD, Dalca AV, et al. White matter hyperintensity burden in acute stroke patients differs by ischemic stroke subtype. Neurology. 2020;95(1):e79–e88. doi: 10.1212/WNL.0000000000009728.
   PubMed Web of Science ®Google Scholar
• Wang T, Jin A, Fu Y, et al. Heterogeneity of white matter hyperintensities in cognitively impaired patients with cerebral small vessel disease. Front Immunol. 2021;12:803504. doi: 10.3389/fimmu.2021.803504.
   PubMed Web of Science ®Google Scholar
• Duering M, Csanadi E, Gesierich B, et al. Incident lacunes preferentially localize to the edge of white matter hyperintensities: insights into the pathophysiology of cerebral small vessel disease. Brain. 2013;136(Pt 9):2717–2726. doi: 10.1093/brain/awt184.
   PubMedGoogle Scholar
• Xia Y, Shen Y, Wang Y, et al. White matter hyperintensities associated with progression of cerebral small vessel disease: a 7-year Chinese urban community study. Aging . 2020;12(9):8506–8522. doi: 10.18632/aging.103154.
   PubMedGoogle Scholar
• Ma C, Liu S, Zhang S, et al. Evidence and perspective for the role of the NLRP3 inflammasome signaling pathway in ischemic stroke and its therapeutic potential (review). Int J Mol Med. 2018;42(6):2979–2990. doi: 10.3892/ijmm.2018.3911.
   PubMed Web of Science ®Google Scholar
• Zhu H, Zhang Y, Feng S, et al. Trends in NLRP3 inflammasome research in ischemic stroke from 2011 to 2022: a bibliometric analysis. CNS Neurosci Ther. 2023; doi: 10.1111/cns.14232.
   Web of Science ®Google Scholar
• Jiang Q, Geng X, Warren J, et al. Hypoxia inducible factor-1α (HIF-1α) mediates NLRP3 inflammasome-dependent-pyroptotic and apoptotic cell death following ischemic stroke. Neuroscience. 2020;448:126–139. doi: 10.1016/j.neuroscience.2020.09.036.
   PubMed Web of Science ®Google Scholar
• He XF, Zeng YX, Li G, et al. Extracellular ASC exacerbated the recurrent ischemic stroke in an NLRP3-dependent manner. J Cereb Blood Flow Metab. 2020;40(5):1048–1060. doi: 10.1177/0271678X19856226.
   PubMed Web of Science ®Google Scholar
• He XF, Li LL, Xian WB, et al. Chronic colitis exacerbates NLRP3-dependent neuroinflammation and cognitive impairment in Middle-aged brain. J Neuroinflammation. 2021;18(1):153. doi: 10.1186/s12974-021-02199-8.
   PubMed Web of Science ®Google Scholar
• Jiang T, Wu M, Zhang Z, et al. Electroacupuncture attenuated cerebral ischemic injury and neuroinflammation through α7nAChR-mediated inhibition of NLRP3 inflammasome in stroke rats. Mol Med. 2019;25(1):22. doi: 10.1186/s10020-019-0091-4.
   PubMedGoogle Scholar
• Ran Y, Su W, Gao F, et al. Curcumin ameliorates white matter injury after ischemic stroke by inhibiting microglia/macrophage pyroptosis through NF-κB suppression and NLRP3 inflammasome inhibition. Oxid Med Cell Longev. 2021;2021:1552127–1552125. doi: 10.1155/2021/1552127.
   PubMedGoogle Scholar
• Lonnemann N, Hosseini S, Marchetti C, et al. The NLRP3 inflammasome inhibitor OLT1177 rescues cognitive impairment in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci U S A. 2020;117(50):32145–32154. doi: 10.1073/pnas.2009680117.
   PubMed Web of Science ®Google Scholar